ライフサイエンスコーパス: malignant tumor

1 patients with extracranial progressive solid malignant tumors .

2 nant tumors, and 3 extraadrenal, including 1 malignant tumor).

3 cancer remains the most lethal gynecological malignant tumor.

4 a is a life-threatening complication of this malignant tumor.

5 om a precancerous or preinvasive lesion to a malignant tumor.

6 herapeutic agents for the management of this malignant tumor.

7 sease while 14 patients (21%) died of second malignant tumor.

8 gan function, and be at low risk of a second malignant tumor.

9 section of a pancreatic, hepatic, or gastric malignant tumor.

10 ification if their biopsy results revealed a malignant tumor.

11 Sebaceous cell carcinoma of the eyelid is a malignant tumor.

12 ed permeability in inflammatory diseases and malignant tumors.

13 oprotein that is highly expressed in several malignant tumors.

14 in the tumorigenesis or metastasis of other malignant tumors.

15 ial drug intervention to treat diet-enhanced malignant tumors.

16 on is correlated with the metastasis of some malignant tumors.

17 s for the most commonly prenatally diagnosed malignant tumors.

18 gression of prostate premalignant lesions to malignant tumors.

19 ffect, are found in most if not all types of malignant tumors.

20 rgeted by deletion and inactivation in human malignant tumors.

21 indispensable roles for CXCR2 in benign and malignant tumors.

22 ogression, growth, and therapy resistance of malignant tumors.

23 to be one of the most indicative markers of malignant tumors.

24 ssemination and angiogenesis of KSHV-induced malignant tumors.

25 on is a potential therapeutic target in many malignant tumors.

26 bidity and mortality that is attributable to malignant tumors.

27 tudies addressing (18)F-FDG repeatability in malignant tumors.

28 rview of the current state of SBRT for solid malignant tumors.

29 adjacent tissues, suggesting that they were malignant tumors.

30 evelopment and/or progression of a number of malignant tumors.

31 linical trials for stage 0 to IV solid organ malignant tumors.

32 ity often correlates with the progression of malignant tumors.

33 mmatory lesions and in many premalignant and malignant tumors.

34 HL disease that displays multiple benign and malignant tumors.

35 existing therapies to consistently eradicate malignant tumors.

36 rve of 0.96 for distinguishing benign versus malignant tumors.

37 oimmune and other inflammatory disorders and malignant tumors.

38 etely separate clustering between benign and malignant tumors.

39 can contribute to the immune surveillance of malignant tumors.

40 resection or radiation therapy of benign and malignant tumors.

41 ng to their development of a unique array of malignant tumors.

42 considered a late event in the evolution of malignant tumors.

43 ary cardiac tumors, and 19 (6%) with primary malignant tumors.

44 agent for preventing or treating peritoneal malignant tumors.

45 hich affected individuals develop benign and malignant tumors.

46 n, polo-like kinase 1, aurora A, and Skp2 in malignant tumors.

47 sgene and spontaneously develops an array of malignant tumors.

48 activities important for the pathobiology of malignant tumors.

49 cial step for the survival and metastasis of malignant tumors.

50 advance towards the effective eradication of malignant tumors.

51 mising treatment option for various types of malignant tumors.

52 dules should be considered in the staging of malignant tumors.

53 potential therapeutic target for intestinal malignant tumors.

54 m, liver, and blood vessels from a number of malignant tumors.

55 independent risk factors in various types of malignant tumors.

56 ntibody D93/TRC093 in patients with advanced malignant tumors.

57 ncogene and a promising drug target in human malignant tumors.

58 ization therapies in GBM, and possibly other malignant tumors.

59 ese progeny can dedifferentiate and generate malignant tumors.

60 unleashes the body's immune response against malignant tumors.

61 ominant disorder characterized by benign and malignant tumors.

62 Such a network has not been identified in malignant tumors.

63 e of this genetically heterogeneous group of malignant tumors.

64 and cannot reliably distinguish benign from malignant tumors.

65 he possible development of resistance to new malignant tumors.

66 estrained cell growth and chemoresistance of malignant tumors.

67 Forty-four of the 115 patients (38%) had malignant tumors, 42 had benign tumors (37%), and 29 (25

68 Fifty percent were for malignant tumors, 45% were for benign lesions, 1.7% were

69 study, 1,007 biopsy samples were reported as malignant tumors (719 gastric, 276 esophageal, and 12 du

70 est that 5hmdC is strongly depleted in human malignant tumors, a finding that adds another layer of c

71 is often used in progressive pediatric solid malignant tumors, a literature review reveals that only

72 There was a 7.9% incidence of malignant tumors after a mean posttransplant follow-up o

73 The fact that this phenomenon is unique to malignant tumors allows their complete discrimination fr

74 barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories

75 epithelial cells in the mucosa give rise to malignant tumors although the interaction between tumor

76 BRCA1/2 carriers may reduce lifetime risk of malignant tumor and eliminate intraperitoneal cancer.

77 ancer (CaP) is the most frequently diagnosed malignant tumor and the second leading cause of cancer d

78 The malignant tumors and benign lesions demonstrated differe

79 ion 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple asp

80 ted the association between TWIST1 and C3 in malignant tumors and in murine embryos.

81 such as CA IX, which has been identified in malignant tumors and is associated with extracellular ac

82 Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-

83 n normal tissues, it is broadly expressed in malignant tumors and may favor tumor immune escape.

84 might also play a role in the progression of malignant tumors and metastasis.

85 as shown biological activity against several malignant tumors and minimal side effects in humans.

86 est uptake of (64)Cu-DOTA-alendronate was in malignant tumors and the lowest uptake in benign tumors

87 reas are a common feature of rapidly growing malignant tumors and their metastases and are typically

88 yes, brain, and spine, as well as benign and malignant tumors and/or cysts of the kidneys, adrenal me

89 ad familial, multiple, extra-adrenal, and/or malignant tumors and/or were younger than 40 years.

90 the effects of APN deficiency in allografted malignant (tumor) and nonmalignant (host) cells on tumor

91 anglioma in 11 cases (8 adrenal, including 2 malignant tumors, and 3 extraadrenal, including 1 malign

92 tions in the same positions were reported in malignant tumors, and a de novo missense substitution in

93 conducted per year, a significant number of malignant tumors are (18)F-FDG PET-negative.

94 Malignant tumors are caused by uncontrolled proliferatio

95 Malignant tumors are common in the colon and breast but

96 Malignant tumors are considered "unresectable" if they a

97 Mounting evidence suggests that malignant tumors are initiated and maintained by a subpo

98 Cutaneous malignant tumors are the most frequent adverse events of

99 Malignant tumors are typically associated with altered r

100 ant peripheral nerve sheath tumors and other malignant tumors, are significant complications in Nf1.

101 Many solid malignant tumors arise on a background of inflamed and/o

102 ments, and changes in those measurements, in malignant tumors before and after therapy.

103 of screening mammography is to detect small malignant tumors before they grow large enough to cause

104 function makes a known contribution to many malignant tumors, but the role of stem cells in benign t

105 effective new strategy for the treatment of malignant tumors by affecting both the endothelial and t

106 Here, we analyzed more than 1600 benign and malignant tumors by immunohistochemical staining of tiss

107 C) accounts for several percent of all adult malignant tumor cases and is directly associated with ov

108 metastasis; however, its roles in regulating malignant tumor cell behavior remain unclear.

109 Transduction of the malignant tumor cell line BT549 on the other hand does n

110 vity has been widely examined in an array of malignant tumor cell types; however, very little is know

111 d in aberrant growth and survival signals in malignant tumor cells and is a validated target for anti

112 ular, are overexpressed on the glycocalyx of malignant tumor cells and sialic acid-mediated cell adhe

113 tromal interaction alters gene expression in malignant tumor cells and stromal cells creating a uniqu

114 s, these nanoparticles can be used to target malignant tumor cells and tumor microenvironments with h

115 We show that EVs released by malignant tumor cells are taken up by less malignant tum

116 inst Axl may block Axl functions not only in malignant tumor cells but also in the tumor stroma.

117 ece of heterogeneous mass including not only malignant tumor cells but also the stroma, the importanc

118 use the strain backgrounds vary, whereas the malignant tumor cells do not, any observed changes in tu

119 Reconstitution of MKP4 expression in malignant tumor cells leads to cell death and tumor supp

120 y malignant tumor cells are taken up by less malignant tumor cells located within the same and within

121 Restoring LIFR expression in highly malignant tumor cells suppresses metastasis by triggerin

122 Exposing rare but highly malignant tumor cells that migrate from the primary tumo

123 By intravital imaging, we show that the less malignant tumor cells that take up EVs display enhanced

124 It is heavily secreted by malignant tumor cells, allowing the protease to serve as

125 ion of a glioma in terms of concentration of malignant tumor cells.

126 type (Ad35) fiber for efficient infection of malignant tumor cells.

127 al cells, leading to both benign (warts) and malignant tumors (cervical cancer).

128 Glioblastomas (GBMs) are malignant tumors characterized by their vascularity and

129 Melanoma is a malignant tumor derived from epidermal melanocytes, and

130 Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue.

131 ic window between normal tissue toxicity and malignant tumor destruction would still offer great valu

132 making them easy to identify, and benign and malignant tumors develop on the skin surface allowing di

133 Malignant tumors develop through multiple steps of initi

134 acetylases (HDACs) have been associated with malignant tumor development and progression in humans.

135 tion of mTORC1 in normal cells could lead to malignant tumor development in several tissues.

136 200 kDa) in various tissues did not lead to malignant tumor development in vivo.

137 Most malignant tumors disrupt the p53 signaling pathway in or

138 ations with municipal mortality due to these malignant tumors during the period 1999-2008.

139 s regulators in platelets of animals bearing malignant tumors exceeds significantly their concentrati

140 mice, spontaneously transformed cells formed malignant tumors expressing GIST markers.

141 These tumors are aggressive malignant tumors for which adjuvant modalities have not

142 of the Ras signaling pathway leads to highly malignant tumor formation for all of the populations.

143 Given that no malignant tumor formation was observed even after a long

144 ility of Notch receptor paralogs to initiate malignant tumor formation, and suggest that glial precur

145 d flow cytometry that, similar to many other malignant tumors, freshly isolated myeloma cells express

146 ma requires accurate differentiation of true malignant tumors from highly atypical lesions, which lac

147 mammary tissue (normal, benign diseases, or malignant tumors) from 87 women with and without breast

148 atistical analysis supports the finding that malignant tumors generally show broad misregulation of m

149 ssive glioma phenotype, along with increased malignant tumor growth and poor survival.

150 tivation of myocardin has been implicated in malignant tumor growth.

151 where it is associated with angiogenesis and malignant tumor growth.

152 a critical functional role for fibrinogen in malignant tumor growth.

153 associated with infectious mononucleosis and malignant tumors, harbors many immune-evasion proteins t

154 Most malignant tumors have elevated levels of Tn, an O-GalNAc

155 These highly malignant tumors have increased activation of the phosph

156 recent clinical results showing that highly malignant tumors have lost the ability to accumulate nCL

157 at is critical for suppressing the growth of malignant tumors; however, the mechanisms allowing ITGA7

158 ancer (CaP) is the most frequently diagnosed malignant tumor in American men, the mechanisms underlyi

159 rs (ECs) are one of the most common types of malignant tumor in females.

160 Neuroblastoma is the most common malignant tumor in infants, and in young infants, 90% of

161 arcoma (KS) is the most frequently occurring malignant tumor in patients infected with HIV.

162 significant substantial risk of a secondary malignant tumor in patients who do not succumb to metast

163 We observed spontaneous malignant tumors in 54 of 93 Bap1-mutant mice (58%) vers

164 he anaphylatoxin C5a, promotes the growth of malignant tumors in a mouse model of cervical carcinoma.

165 ses that are associated with both benign and malignant tumors in animals and humans.

166 h Pten loss (Pten(IEKO);Tgfbr2(IEKO)) led to malignant tumors in both the small intestine and colon i

167 aviridae that are associated with benign and malignant tumors in humans and animals.

168 nfertility, neurodegenerative disorders, and malignant tumors in humans.

169 t that PTEN may safeguard against developing malignant tumors in patients with TSC deficiency.

170 distal pancreatectomy for benign or lowgrade malignant tumors in the body/tail of the pancreas were i

171 istal pancreatectomy for benign or low-grade malignant tumors in the body/tail of the pancreas.

172 Glioma accounts for 80% of all primary malignant tumors in the central nervous system, and thes

173 tract is the cause of a number of benign and malignant tumors in these locations, including cervical

174 nderestimates K(trans) for each of the seven malignant tumors in this population.

175 ceptors suppress the emergence and growth of malignant tumors in vivo.

176 Furthermore, malignant tumors in younger patients were highly fatal (

177 Malignant tumors included melanoma (12%), squamous cell

178 The few malignant tumors included melanoma and lymphoma.

179 n Hippel-Lindau (VHL) can lead to benign and malignant tumors, including clear-cell renal cell carcin

180 2 (HMGA2) is found in a number of benign and malignant tumors, including the clonal PIGA(-) cells in

181 be upregulated or activated in a variety of malignant tumors, including those from thyroid, colon an

182 ssociated with the expansion of rare, highly malignant tumor-initiating stem cells (TISCs) through po

183 s support the inappropriate growth of intact malignant tumors is incompletely understood.

184 could explain these BRAF wild-type secondary malignant tumors is still unknown.

185 Metastasis, the cardinal feature of malignant tumors, is an important clinical variable in p

186 tion is deregulated in transformed cells and malignant tumors, it has not been determined whether thi

187 performed more frequently, even for larger, malignant tumors located in challenging locations.

188 Certain malignant tumors may also depend on cellular hierarchies

189 haracteristics that differentiate benign and malignant tumors may inform our understanding of the mal

190 Malignant tumors metabolize glucose to lactate even in t

191 viduals and patients with different types of malignant tumors, mostly carcinomas, where the increased

192 ses: fibroma (n = 30), rhabdomyoma (n = 14), malignant tumor (n = 12), hemangioma (n = 9), thrombus (

193 18) or liver (n = 12) resection, mainly for malignant tumors (n = 29).

194 All malignant tumors (n = 32) were hypermutant.

195 Malignant tumors negatively affect early and late surviv

196 ith no liver disease who had surgery for non malignant tumor (normal hepatocytes).

197 Osteosarcoma is the most common primary malignant tumor of bone.

198 Gastric cancer (GC), an aggressive malignant tumor of the alimentary tract, is a leading ca

199 a (PLGA) is the second most frequent type of malignant tumor of the minor salivary glands.

200 In 26 malignant tumors of 0.6-2.5 cm in size, Hb(T) was signif

201 Liposarcomas are rare malignant tumors of adipocytic differentiation.

202 Malignant tumors of adrenal glands should be taken into

203 a critical cellular event for metastasis of malignant tumors of epithelium origin.

204 genetic disorder characterized by benign and malignant tumors of neural crest origin.

205 arcoma family of tumors (ESFT) is a group of malignant tumors of soft tissue and bone sharing a chrom

206 positive and negative predictive values for malignant tumors of the conjunctiva and eyelid margin we

207 examination conducted with the slitlamp for malignant tumors of the eyelid margin (98% vs 92%) and c

208 amilial syndrome characterized by benign and malignant tumors of the kidney, central nervous system,

209 perative strategy for oncologic resection of malignant tumors of the liver and an optimal postoperati

210 Recommendations for resection of malignant tumors of the liver based on traditional consi

211 The operative strategy for resection of malignant tumors of the liver should address the key com

212 man papillomaviruses (HPVs) cause benign and malignant tumors of the mucosal and cutaneous epithelium

213 s are prone to the development of benign and malignant tumors of the nervous system.

214 TKTL1 is dysregulated in malignant tumors of the ocular adnexa, and enhanced expr

215 euroendocrine tumors (NETs) are uncommon but malignant tumors of the thymus gland that are usually as

216 There have been two malignant tumors: one thyroid cancer within the radiatio

217 less, mutant p53 mice are viable and develop malignant tumors only on adulthood.

218 ancer research to date have focused on fully malignant tumors or cancer cell lines, but the potential

219 linical manifestations, including benign and malignant tumors, osseous dysplasias, and characteristic

220 e the mediastinum (group C, n=16), and other malignant tumors outside the thymus (group D, n=38).

221 11 years for benign tumors and 14 years for malignant tumors (P = .005), with mean difference of 3 y

222 sion correlated with the patient outcomes in malignant tumors (P = 0.045).

223 ith benign lesions vs 18 of 44 patients with malignant tumors [P < .001]), and internal vascularizati

224 ith benign lesions vs 22 of 44 patients with malignant tumors [P < .001]), irregular margins (26 of 8

225 ith benign lesions vs 42 of 44 patients with malignant tumors [P < .001]).

226 lead to genomic instability and ultimately a malignant tumor phenotype.

227 stance to therapy, poorer survival, and more malignant tumor phenotypes.

228 al tissues of various lineages and benign or malignant tumors (predominantly colon, melanoma, ovarian

229 parently not SXR) is significant in only the malignant tumors, presumably because of angiogenic capil

230 We also identified six genes driving malignant tumor progression and a new human CRC tumor-su

231 es-9 (MMP-9), which has been associated with malignant tumor progression and metastasis by matrix deg

232 elial-mesenchymal transition (EMT) underlies malignant tumor progression and metastatic spread by ena

233 xpressed in cancer cells and associated with malignant tumor progression and poor outcome.

234 data indicate that RES suppresses UV-induced malignant tumor progression in p53(+/-)/SKH-1 mice and t

235 a play a central and multifunctional role in malignant tumor progression, and targeting mitochondria

236 like features, and ultimately contributes to malignant tumor progression.

237 ation has been recognized as one hallmark of malignant tumor progression.

238 function (haploinsufficiency) fosters benign malignant tumor progression.

239 ta, whose activities are dysregulated during malignant tumor progression.

240 in tumor microenvironment may contribute to malignant tumor progression.

241 or microenvironment has significant roles in malignant tumor progression.

242 e fibroblasts to express genes that promoted malignant tumor progression; indeed, treatment with reco

243 The finding suggests that malignant tumors promote invasion/metastasis not only th

244 Malignant tumors release growth factors such as VEGF-C t

245 ogic settings including retinal ischemia and malignant tumors, robust angiogenesis occurs despite the

246 Malignant tumors secrete large numbers of extracellular

247 other benign tumors (SMR 4.63, P=0.003), and malignant tumors (SMR 101, P<0.0001) had significantly p

248 based on diagnostics imaging between MO and malignant tumors, such as parosteal sarcoma, synovial sa

249 d mitotic APC/C substrates and regulators in malignant tumors suggests that analysis of this pathway

250 In conclusion, although malignant tumors tend to exhibit increased rigidity, int

251 Malignant tumors tend to occur in older patients and dem

252 inoma (ccRCC) is a common aggressive urinary malignant tumor that cannot be easily diagnosed at an ea

253 Retinoblastoma is a highly invasive malignant tumor that often invades the brain and metasta

254 s potentially applicable to several types of malignant tumors that demonstrate chemoresistance and ma

255 Eighty percent of malignant tumors that develop in the central nervous sys

256 nchymal GBM subtype in particular are highly malignant tumors that frequently exhibit regions of seve

257 primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of

258 primary extracranial, nonhematopoietic solid malignant tumors that progressed after at least 2 lines

259 ically and clinically heterogeneous group of malignant tumors that resemble developing skeletal muscl

260 the acidic extracellular microenvironment of malignant tumor tissue.

261 by biopsy), size, and TNM Classification of Malignant Tumors (TNM).

262 yed (18)F-FDG PET imaging typically enhances malignant tumor to background.

263 Metastasis, the aggressive spread of a malignant tumor to distant organs, is a major cause of d

264 being used to monitor the early response of malignant tumors to chemotherapy.

265 or effect primarily in cells originated from malignant tumors: transformed cell line of non-cancer or

266 Sixty-eight malignant tumors treated with RF ablation were identifie

267 lls, the prevalence and growth of benign and malignant tumors, treatment effectiveness and costs, and

268 rcinoma but were also detected in four other malignant tumor types, including adenocarcinoma of the c

269 AP1 are predisposed to a range of benign and malignant tumor types, including malignant mesothelioma,

270 of infected individuals develop a subsequent malignant tumor, underscoring the important role that ho

271 but also in their sporadic counterparts and malignant tumors unrelated to the NF2 syndrome such as m

272 r central nervous system tumors, but also in malignant tumors unrelated to the NF2 syndrome, indicati

273 These cells formed malignant tumors upon s.c. injection into immunocompromi

274 ns purified from experimental xenografts and malignant tumors using antibody- or lectin-affinity colu

275 SUVmax of the benign and malignant tumors was compared.

276 associated with seprase could be involved in malignant tumors, we used a mammalian expression system

277 Patients >/= 70 years old with a malignant tumor were included if a new cancer event occu

278 Forty-eight patients with 51 malignant tumors were assessed.

279 Features of benign and malignant tumors were compared.

280 erative factors of patients with and without malignant tumors were compared.

281 Ten dogs with biopsy-verified spontaneous malignant tumors were included for imaging.

282 rsus nonneoplastic lesions and benign versus malignant tumors were parenchymal microlithiasis (26 of

283 the 19th, and for most of the 20th century, malignant tumors were removed by mutilating radical anat

284 ations in 55 pediatric patients with non-CNS malignant tumors were reviewed.

285 Malignant tumors were seen only in adolescent boys.

286 bnormalities even at early passages and form malignant tumors when transplanted in vivo.

287 in a tissue and the clinical detection of a malignant tumor, whereas the linear phase reflects event

288 of immune evasion in chronic infections and malignant tumors will continue to help in the goal of op

289 rcinoma (SDC) is an uncommon, but aggressive malignant tumor with a high mortality rate.

290 Human uveal melanoma (UM) is a major ocular malignant tumor with high risk of metastasis and require

291 c alterations, resulting in the formation of malignant tumors with aggressive local invasion and epit

292 cinoma (cSCC) is one of the most common skin malignant tumors with an increasing incidence.

293 Malignant tumors with deregulated FGF-2 expression such

294 mising option for differentiation therapy in malignant tumors with dysregulated HDAC3 activity.

295 , most PinX1+/- mice spontaneously developed malignant tumors with evidence of chromosome instability

296 mas occurring at transition zones are highly malignant tumors with poor prognosis.

297 Vascular leiomyosarcomas are aggressive malignant tumors, with high recurrence rates.

298 14 teratomas) generated major dysplasia and malignant tumors, with yolk sac tumors and embryonal car

299 ar carcinoma (HCC) is one of the most common malignant tumors worldwide and is almost uniformly fatal

300 nd breast cancers (TC, BC) are common female malignant tumors worldwide.